These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 3566358

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism.
    Toscano V, Bianchi P, Balducci R, Guglielmi R, Mangiantini A, Lubrano C, Sciarra F.
    Clin Endocrinol (Oxf); 1992 Feb; 36(2):197-202. PubMed ID: 1533185
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The effect of combined oral contraception with or without spironolactone on bone mineral density of hyperandrogenic women.
    Gregoriou O, Bakas P, Konidaris S, Papadias K, Mathiopoulos D, Creatsas G.
    Gynecol Endocrinol; 2000 Oct; 14(5):369-73. PubMed ID: 11109976
    [Abstract] [Full Text] [Related]

  • 26. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.
    Anttila L, Koskinen P, Kaihola HL, Erkkola R, Irjala K, Ruutiainen K.
    Fertil Steril; 1992 Oct; 58(4):697-702. PubMed ID: 1426312
    [Abstract] [Full Text] [Related]

  • 27. A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome.
    Buvat J, Buvat-Herbaut M, Marcolin G, Racadot A, Fourlinnie JC, Beuscart R, Fossati P.
    J Clin Endocrinol Metab; 1986 Jul; 63(1):119-24. PubMed ID: 3519644
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Hirsutism--a low dose spironolactone therapy.
    Vĕtr M.
    Acta Univ Palacki Olomuc Fac Med; 1989 Jul; 122():239-45. PubMed ID: 2530821
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Available anti-androgens for treating skin hyperandrogenism].
    Pugeat M.
    Rev Fr Gynecol Obstet; 1989 Jun; 84(6):505-8. PubMed ID: 2528199
    [Abstract] [Full Text] [Related]

  • 35. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
    Moghetti P, Castello R, Zamberlan N, Rossini M, Gatti D, Negri C, Tosi F, Muggeo M, Adami S.
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1250-4. PubMed ID: 10199763
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
    Heikinheimo O, Gordon K, Williams RF, Hodgen GD.
    Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
    [Abstract] [Full Text] [Related]

  • 37. Role of progesterone deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome.
    Fiad TM, Cunningham SK, McKenna TJ.
    Eur J Endocrinol; 1996 Sep; 135(3):335-9. PubMed ID: 8890725
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The grade of hirsutism correlated to serum androgen levels and hormonal indices.
    Ruutiainen K, Erkkola R, Kaihola HL, Santti R, Irjala K.
    Acta Obstet Gynecol Scand; 1985 Sep; 64(8):629-33. PubMed ID: 2938400
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.